Fig. 3

Impact of alterations on telomeric content in PCAWG dataset and pan-cancer. A. Boxplots showing the impact of alterations within ATRX/DAXX, TERTp, and RAD21 on the telomeric content of samples in the PCAWG dataset. Diseases were selected based on the results shown in Figs. 1C and 2A. For RAD21, Prost-AdenoCA, Breast-AdenoCA, Breast-LobularCA, Breast-DCIS, and Lung-AdenoCA were included. For ATRX/DAXX, CNS-GBM, CNS-LGG, and Panc-Endocrine were included and for TERTp, the analysis included CNS-GBM, CNS-LGG, and Skin-Melanoma samples. WT, wild-type; Alt, altered. ** signifies p<0.01 and **** p<0.0001. Boxplots showing the impact of alterations in ATRX, DAXX, RAD21, HGF, TERC, and TERTp on telomeric content of all samples within the FMI dataset (B) and the PCAWG dataset (C). For B and C, all samples with available telomeric content measurements were included regardless of their disease ontology. Dunn’s test, a non-parametric pairwise multiple comparisons test based on rank sums, was performed with a Bonferroni correction to assess differences between multiple sample groups. Only comparisons against WT are shown. **** signifies p<0.0001